Rheumatoid arthritis and multiple myeloma as comorbidity. Is tocilizumab a therapy option?

Multiple myeloma (MM) is a disease of the elderly with an incidence of 4/100,000 per year and can occur as a comorbidity especially in elderly patients with rheumatoid arthritis (RA). For MM and also for RA interleukin-6 (IL-6) is a pathogenetically important cytokine in both disease events. This ar...

Full description

Saved in:
Bibliographic Details
Published in:Zeitschrift für Rheumatologie 2012-01, Vol.71 (1), p.78
Main Authors: Schütz, N, Märker-Hermann, E
Format: Article
Language:ger
Subjects:
Aged, 80 and over
Antibodies, Monoclonal, Humanized - administration & dosage
Antirheumatic Agents - administration & dosage
Arthritis, Rheumatoid - complications
Arthritis, Rheumatoid - drug therapy
Arthritis, Rheumatoid - pathology
Female
Humans
Multiple Myeloma - complications
Multiple Myeloma - drug therapy
Multiple Myeloma - pathology
Treatment Outcome
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Multiple myeloma (MM) is a disease of the elderly with an incidence of 4/100,000 per year and can occur as a comorbidity especially in elderly patients with rheumatoid arthritis (RA). For MM and also for RA interleukin-6 (IL-6) is a pathogenetically important cytokine in both disease events. This article presents the case of a female patient who achieved sustained remission of RA and stabilization of MM with quantitative reduction of paraprotein by treatment with tocilizumab. The question whether tocilizumab represents a meaningful treatment approach for treatment of RA when MM is also present will be discussed.
ISSN:1435-1250
DOI:10.1007/s00393-011-0931-2